20 results about "Bronchial epithelium" patented technology

The application discloses a percutaneous lung puncture path planning method and device based on lung segment level blood vessel structure constraint, and the method comprises the following steps: performing isotropic resampling, lung lobe segmentation and bronchial tree extraction on CT image data to generate a three-dimensional lung dissection model; inputting the three-dimensional lung dissection model into a lung segment semantic segmentation module to output a lung segment boundary; reconstructing the topological connection relationship between lung segment level blood supply arteries and drainage veins from the lung segment boundary to obtain a structured lung segment level blood vessel atlas; constructing a dynamic puncture risk field voxel map according to the structured lung segment level blood vessel atlas; sampling a plurality of candidate needle entry points in a surface feasible needle entry region to generate an initial path set in the three-dimensional lung dissection model; and weighting the path length, cumulative risk value, puncture angle penalty and high-density lung tissue volume according to a multi-objective optimization function to output a final puncture path. The application significantly improves the safety boundary and clinical applicability of percutaneous lung puncture.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The application discloses application of lactosylceramide in regulating inflammation related to bronchiectasis Pseudomonas aeruginosa infection. The application discloses, for the first time, the role of LacCer in amplification of inflammation related to bronchiectasis infection, proposes a new infection control mechanism from the perspective of metabolic regulation, and indicates that LacCer participates in regulation of inflammation by regulating the NLRP3 inflammasome related pathway, thereby providing a direction for targeted intervention. On this basis, the application further proves, through in-vivo experiments, that inhibition of LacCer synthesis can intervene in inflammation and lung injury related to bronchiectasis infection, thereby providing a new potential treatment strategy for control of inflammation related to bronchiectasis infection.

FIELD: pediatrics and pulmonology.SUBSTANCE: used to predict the risk of severe bronchial asthma in children. Anamnesis is collected, blood is taken, and the child's blood is tested in a laboratory. From the anamnesis, the duration of the disease in years and the number of exacerbations over the current 12 months in points are specified. The peak expiratory flow rate is measured using a peak flow meter, %. The concentration of connexin 43 (CX43), ng / ml, is determined in the child’s blood serum at the time of inclusion in the study. The prognosis for the risk of severe bronchial asthma in children P is calculated using the stated formula. If the P value is 0.52 or higher, a high risk of severe bronchial asthma is predicted.EFFECT: method provides the possibility of increasing the accuracy and reliability of the prognosis of the severity of bronchial asthma in children by taking into account the declared clinical symptoms and risk factors for bronchial asthma in children and adolescents of both sexes who do not have signs of a severe course of the disease at the time of examination.1 cl, 4 ex

This invention discloses a method for preparing and applying a Pasteurella-Bordetella nanovaccine, belonging to the field of biomedical technology. The method includes the following steps: emulsifying epigallocatechin gallate, an antigen aqueous phase, and soybean oil under high-speed shearing, followed by homogenization to form a stable oil-in-water emulsion, which is the Pasteurella-Bordetella nanovaccine. Challenge experiments confirmed that the ESO vaccine achieved a protection rate of up to 90% against Pasteurella multocida and Bordetella bronchiseptica, significantly superior to the 40%-70% protection rate of the aluminum adjuvant group. Simultaneously, it significantly reduced the bacterial load in the lungs, demonstrating excellent clinical protective effects. This invention, through the innovative combination of EGCG and vegetable oil, overcomes the limitations of traditional adjuvants in terms of immunogenicity, safety, and single function, providing a highly efficient and safe new vaccine solution for the prevention and control of Pasteurella multocida and Bordetella multocida infections.

The present application relates to the technical field of thermoplastic elastomer, in particular to a disposable visual double-lumen bronchial cannula and a preparation method thereof.The ethylene-propylene thermoplastic elastomer, polypropylene resin, antibacterial silver material and antibacterial zinc oxide material are mixed, and then melt extrusion, cooling and traction are carried out to obtain a pipe material.The pipe material is sequentially subjected to water washing, alcohol washing, drying and plasma treatment to obtain a pretreated pipe material.The antibacterial hydrogel solution is obtained by adding hydroxyethyl acrylamide, acrylic acid, polyvinylpyrrolidone, propenyl quaternary ammonium salt, allyl triphenyl phosphonium bromide and 1-allyl imidazole.The pretreated pipe material is soaked in the antibacterial hydrogel solution, and then the finished product is obtained after ultraviolet irradiation.The finished product prepared by the present application has excellent antibacterial property and lubricity, and therefore has a wide application prospect in the technical field of thermoplastic elastomer.

This invention belongs to the field of traditional Chinese medicine composition technology, specifically relating to a traditional Chinese medicine composition and preparation for treating bronchial asthma. The traditional Chinese medicine composition consists of the following raw materials in parts by weight: 9-11 parts Perilla seed, 6-8 parts White mustard seed, 6-8 parts Lepidium seed, 6-8 parts Radish seed, 4-6 parts Scutellaria baicalensis, 9-11 parts Houttuynia cordata, 3-5 parts Prepared Ephedra, 4-6 parts Fresh Fritillaria cirrhosa, 5-7 parts Magnolia officinalis, and 3-5 parts Schisandra chinensis. This invention not only benefits lung qi and promotes proper lung function, but also addresses the issue that impaired lung function can lead to stagnant heat and dampness. Therefore, Scutellaria baicalensis and Houttuynia cordata are used to clear heat, purge fire, and dry dampness. Persistent wheezing inevitably depletes lung qi, damages lung fluids, and harms kidney essence. Therefore, Schisandra chinensis is used to astringe the lungs, nourish the kidneys, generate fluids, and consolidate essence, restoring normal lung function and benefiting both the lungs and kidneys, thus relieving wheezing.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof:or a pharmaceutically acceptable salt thereof.  The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI). 

The present application relates to the technical field of medical image analysis, and provides a lung image registration method and system based on a cross-scale reverse refinement mechanism, which comprises the following steps: acquiring a moving image and a fixed image of a lung, obtaining a multi-scale moving feature map and a multi-scale fixed feature map through an encoder respectively, and obtaining a multi-scale deformation field through a deformation field estimator; uniformly up-sampling the low-scale deformation field to the same resolution as the highest-scale deformation field, taking the highest-scale deformation field as a guide signal, guiding and correcting each up-sampled deformation field by using a cross-scale deformation refinement network based on KAN, and obtaining a high-resolution guided and corrected multi-scale deformation field; generating a final deformation field by using an adaptive weight fusion network, processing the moving image, obtaining a deformed moving image, and aligning the deformed moving image with the fixed image in the spatial structure. The present application ensures the accurate alignment of local anatomical structures such as lung parenchyma capillary vessels and bronchial tree.

The present invention relates to a method and a preparation for treating inflammatory diseases of the respiratory tract in horses, in particular equine asthma, by inhalational administration of aviptadil or another receptor agonist of the VIP receptor (VPAC1 and VPAC2 receptors). Vasoactive intestinal peptide (VIP) is a neuropeptide with anti-inflammatory and bronchodilatory properties, which, when synthetically produced (INN = aviptadil), can be used specifically to reduce inflammation and relax the respiratory muscles. In a preferred embodiment, the effect of aviptadil is enhanced by the simultaneous or prior administration of N-acetylcysteine ​​(ACC). Aviptadil is suitable for treating horses because equine VIP and human VIP are sequence-identical.

Nitrile derivative compounds represented by Chemical Formula I, stereoisomers thereof, deuteration products, cocrystals, solvates, or pharmaceutically acceptable salts are provided, wherein each group is defined as in the detailed description. The compounds have dipeptidyl peptidase 1 inhibitory activity and can be used to manufacture drugs for treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, chronic obstructive pulmonary disease and other diseases. [Chemical Formula I]

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

This invention discloses the application of a sulfonamide derivative in the preparation of a drug for treating respiratory syncytial virus (RSV) pneumonia, belonging to the field of biomedical technology. This invention is the first to discover that 3-(4-methoxyphenyl)-N-[4-[(4-methylpyrimidin-2-yl)sulfonylmethyl]alanine has significant anti-RSV activity, effectively reducing the lung index in RSV-infected mice, improving the pathological lesions in the lungs and bronchi of mice, and significantly reducing the expression of RSV viral load in mouse lung tissue, demonstrating a clear therapeutic effect on RSV-induced pneumonia in mice. This not only provides a novel application direction and experimental evidence for 3-(4-methoxyphenyl)-N-[4-[(4-methylpyrimidin-2-yl)sulfonylmethyl]alanine, but also provides a new and effective candidate drug for the clinical treatment of RSV pneumonia, possessing significant biomedical application value.

This invention relates to the field of pathogen infection detection technology, specifically a method for visually tracking human bronchial organoids infected with Mycoplasma pneumoniae. It includes the following steps: (1) Constructing human bronchial organoids: culturing mature human bronchial organoids with cavities, the organoids comprising ciliated cells, basal cells, goblet cells, and Club cells, having a polarized three-dimensional structure with the apex facing outwards; (2) Mycoplasma pneumoniae culture and fluorescent labeling: Mycoplasma pneumoniae is amplified and cultured in MP complete medium, and then fluorescently labeled using CellTrace far-infrared cell staining solution; (3) Co-culture for infection: Mycoplasma pneumoniae fluorescently labeled in step (2) is co-cultured with the human bronchial organoids from step (1) for infection; (4) Live cell dynamic fluorescence tracking: Non-invasive in situ continuous imaging is performed on the human bronchial organoids infected by MP in step (3). This invention can achieve non-invasive dynamic tracking of the entire process of MP infection.

Disclosed herein are compounds useful for the inhibition of STAT6. The compounds have a general Formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) and (II) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, diseases / disorders related to the activity of STAT6, such as an allergic disease or an inflammatory disease, including but not limited to atopic dermatitis or bronchial asthma. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I) and (II).

This invention relates to methods for treating or preventing asthma by administering an IL-4R antagonist, and provides methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate to severe asthma, persistent asthma, etc.) and related conditions (e.g., ABPA, ABPA comorbidity with asthma, ABPA comorbidity with cystic fibrosis (CF), ABPA comorbidity with both asthma and CF) in subjects. A method is provided comprising administering a therapeutic composition to a subject in need, said therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or an antigen-binding fragment thereof.

This disclosure relates to compositions and methods for improving the pulmonary delivery of therapeutic nucleic acids, such as DNA and mRNA, by inhalation, intranasal administration, intratracheal instillation, bronchial instillation, and / or topical application, thereby enhancing transfection efficiency and thus improving the efficacy of therapeutic nucleic acids. Transfection efficiency enhancers, including but not limited to 2-mercaptoethanesulfonate or cysteine, are administered via intratracheal, bronchial instillation, and / or topical application.

The application discloses application of a wild chrysanthemum essential oil effective component combination in preparation of a medicine for preventing and treating acute lung injury, and particularly relates to the technical field of biological medicines, wherein the wild chrysanthemum essential oil effective component comprises beta-farnesene, 4-terpenol, artemisia oil, wild chrysanthemum alcohol and carvomenthone, and in an acute lung injury model, the wild chrysanthemum essential oil effective component can significantly regulate the survival state of lung epithelial cells, improve the phenomenon of cell activity decline, and effectively maintain the stability of mitochondrial membrane potential (Delta Psi m). In an acute lung injury mouse model, the wild chrysanthemum essential oil effective component combination can significantly improve the pathological injury of lung tissue, and significantly inhibit the expression of inflammatory mediators in bronchoalveolar lavage fluid (BALF). In summary, the wild chrysanthemum essential oil effective component combination can be applied in preparation of an anti-acute lung injury medicine.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.